News

Press Releases

December 2, 2024
OncoC4 Announces FDA Clearance of IND Application for Potential Best-in-Class PD-1/VEGF Bispecific AI-081 in Advanced Solid Tumors

ROCKVILLE, Maryland, December 2, 2024 (GLOBE NEWSWIRE) –– OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer and neurological […]

Read more
October 1, 2024
OncoC4 in the News

Our merger announcement of OncoC4 with AcroImmune has generated great excitement from multiple major news outlets, and here are some […]

Read more
September 25, 2024
OncoC4 and AcroImmune Announce Merger

ROCKVILLE, Maryland, September 25, 2024 (GLOBE NEWSWIRE) – OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, and […]

Read more
August 30, 2024
OncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors

ROCKVILLE, Maryland, USA, August 30, 2024 — OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer and […]

Read more
April 22, 2024
OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors

ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune checkpoint and prevent […]

Read more
Scroll to Top